The Association of Periprocedural Hypertension and Adverse Outcomes in Patients Undergoing Catheter-Directed Thrombolysis

Annals of Vascular Surgery

Volumn 24, Issue 5, 2010, Pages 609-614

  Agle, Steven C ^a   McNally, Michael M ^a   Powell, C Steven ^a   Bogey, William M ^a   Parker, Frank M ^a   Stoner, Michael C ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; FIBRINOGEN; HEPARIN; WARFARIN; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTERY BYPASS; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CATHETER DIRECTED THROMBOLYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DEATH; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEMATOMA; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; UNIVARIATE ANALYSIS; UPPER GASTROINTESTINAL BLEEDING; ADVERSE EFFECTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPLICATION; INTERVENTIONAL ULTRASONOGRAPHY; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; CATHETERIZATION, PERIPHERAL; CHI-SQUARE DISTRIBUTION; FIBRINOLYTIC AGENTS; HEMATOMA; HUMANS; HYPERTENSION; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL; VENOUS THROMBOSIS;

EID: 77953326661     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2009.12.011     Document Type: Article

References (17)

1. Sugimoto K., Hofmann L.V., Razavi M.K., et al. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg 37 (2003) 512-517
2. Bero C.J., Cardella J.F., Reddy K., et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. J Vasc Interv Radiol 6 (1995) 571-577
3. Shortell C.K., Queiroz R., Johansson M., et al. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. J Vasc Surg 34 (2001) 854-859
4. Castaneda F., Li R., Young K., Swischuk J.L., Smouse B., and Brady T. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. J Vasc Interv Radiol 13 (2002) 577-580
5. Ouriel K., Katzen B., Mewissen M., et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 11 (2000) 849-854
6. Mewissen M.W., Seabrook G.R., Meissner M.H., Cynamon J., Labropoulos N., and Haughton S.H. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 211 (1999) 39-49
7. Ouriel K. Thrombolytic therapy for acute peripheral arterial occlusion. In: Hallett J., Mills J., Earnshaw J., and Reekers J.A. (Eds). Comprehensive Vascular and Endovascular Surgery (2004), Mosby, New York p. 213-214-221
8. Giannini D., and Balbarini A. Thrombolytic therapy in peripheral arterial disease. Curr. Drug Targets Cardiovasc. Haematol. Disord 4 (2004) 249-258
9. Razavi M.K., Lee D.S., and Hofmann L.V. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies.[republished from J. Vasc Interv. Radiol. 2003;14:1491-501; PMID: 14654482]. J Vasc Interv Radiol 15 1 Pt 1 (2004) 13-23
10. Semba C.P., Murphy T.P., Bakal C.W., Calis K.A., and Matalon T.A. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 11 2 Pt 1 (2000) 149-161
11. Ouriel K., Gray B., Clair D.G., and Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 11 (2000) 295-298
12. Thomas S.M., Buckenham T.M., and Belli A.M. Update on endovascular management of arterial occlusive disease. Hosp. Med 59 (1998) 543-548
13. Gilligan A.K., Markus R., Read S., et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 33 (2002) 2236-2242
14. Tanne D., Kasner S.E., Demchuk A.M., et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 105 (2002) 1679-1685
15. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann.Surg 220 (1994) 251-266 discussion 266-268
16. Arepally A., Hofmann L.V., Kim H.S., et al. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol 13 (2002) 45-50
17. McNamara T.O., Dong P., Chen J., et al. Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions. Tech Vasc Interv Radiol 4 (2001) 92-98